Adoptive Immunotherapy for Epstein-Barr virus associated Nasopharyngeal Carcinoma

The University of Hong Kong0 个研究点目标入组 30 人开始时间: 2009年8月7日最近更新: 2021年10月26日

适应症

试验速览

暂无简介。

•1. Age 15 years or above.
•2. Geographically accessible for follow up
•3. Informed consent (from patient, or patient and parent/guardian if aged < 16 years) Approved hospital interpreters will be used for patients who do not have sufficient understanding of English for informed consent to be obtained without the use of an interpreter.
•4. Eastern Cooperative Oncology Group performance status 0, 1, 2 or 3
•5. Previously diagnosed with stage II, III or IV nasopharyngeal carcinoma (NPC)
•6. Life expectancy of at least 3 months.

•1. EBV negative tumour
•2. Inability to identify an LMP/EBNA1 peptide to stimulate CTL cultures
•3. Positive serology for human immunodeficiency virus (HIV)
•4. Serology indicating active Hepititis B Virus (HBV) infection or carrier status for HBV (N.B. Positive serology for HBV indicating previous but cleared infection with HBV would not be an exclusion criteria.)
•5. Serology indicating active Hepititis C Virus (HCV) infection
•6. Significant non –malignant disease (e.g. severe cardiac or respiratory dysfunction)
•7. Psychiatric, addictive or any conditions which may compromise the ability to participate in this trial
•8. Prior cancers, except those diagnosed > 5 years ago with no evidence of disease recurrence and clinical expectation of recurrence of < 5%, or successfully treated non-melanoma skin cancer, or carcinoma in situ of the cervix.
•9. Currently receiving immunosuppressive therapy, including corticosteroids.
•10. Pregnancy, or unwilling to use adequate contraception.

发起方